BioSpace News Archive

Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended March 31, 2020 (“Q3 FY 2020”).

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported financial results for the first quarter ended Mar. 31 and provided operational updates, including measures taken by the company in response to the COVID-19 pandemic.

Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced the presentation of preclinical data for its Krabbe disease program.

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Quarter1-2020 corporate update call on Tuesday, May 19th at 5:00 PM ET.

ECMOHO Limited (Nasdaq: MOHO) (“ECMOHO” or the “Company”), a leading integrated solutions provider in the rapidly growing non-medical health and wellness market in China, hosted a summit in Shanghai on May 11 on the theme of “Smart Health Enables Faster Growth”.

Roche (SIX: RO, ROG)(OTCQX: RHHBY) today announced the launch of the new KAPA Target Enrichment portfolio, consisting of both exome and custom target enrichment solutions for sequencing.

Shanghai ChemPartner announced they have entered into a non-exclusive agreement with the Mount Sinai Health System to assist in a trial production run of a component of the Mount Sinai COVID-19 serological assay that recently received Emergency Use Authorization from the U.S. Food and Drug Administration for use in Mount Sinai’s lab during the COVID-19 emergency declaration.

PathologyWatch announced today a $5M series A funding led by SpringTide Investments and Rock Creek Capital with additional funding by individual investors. PathologyWatch is emerging as the groundbreaking leader of intuitive, easy-to-implement digital dermatopathology solutions that can speed the diagnostic process while reducing costs to clinics and enhancing patient care.

Aldevron, the leading plasmid DNA manufacturing company, has expanded its leadership team by appointing Dr. James Brown President of its Research Grade nucleic acids business unit.

Pfizer Inc. (NYSE: PFE) today announced that new data from clinical trials of 18 approved and investigational medicines will be presented virtually at the ASCO20 Virtual Scientific Program, from May 29-May 31.